Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Gene Med ; 8(3): 253-64, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16288493

RESUMO

BACKGROUND: Efficient gene transfer to bone marrow derived mesenchymal stem cells (MSC) would provide an important opportunity to express potent anticancer agents in the tumour microenvironment because of their contribution to the tumour stroma. METHODS: HIV-based lentiviral vectors were pseudotyped with four different envelope proteins; amphotropic murine leukaemia virus (ampho), murine leukaemia virus (10A1), feline endogenous virus (RD114), and the vesicular stomatitis virus glycoprotein (VSVG). These pseudotypes were examined for transduction efficiency in human bone marrow derived MSC. The effect of lentiviral expression of truncated soluble vascular endothelial growth factor decoy receptor (tsFlk-1) in MSC on growth of Raji cells was determined, both in vitro and in vivo. RESULTS: All lentiviral vectors produced significant levels of transduction at an multiplicity of infection (MOI) of 1, those bearing the RD114 envelope glycoprotein consistently produced higher transduction levels (mean 70 +/- 6%) compared with the other pseudotyped lentiviral vectors, although there was significant inter-donor variation. Stable transgene expression was achieved after multiple rounds of transduction with VSVG-pseudotyped particles, without alteration in the differentiative capacity of transduced cells. Co-injection of MSC stably expressing tsFlk-1 with Raji Burkitt's lymphoma cells significantly impaired subcutaneous tumour growth in immunodeficient mice when compared to controls where either unmanipulated MSC or GFP-expressing MSC were used. CONCLUSIONS: Human MSC are easily transduced by pseudotyped lentiviral particles but there is inter-donor variation in transduction efficiency. Gene-modified MSC expressing a gene of therapeutic potential can moderate growth of haematological malignancies.


Assuntos
Linfoma de Burkitt/genética , Linfoma de Burkitt/terapia , Técnicas de Transferência de Genes , Lentivirus/genética , Transplante de Células-Tronco Mesenquimais/métodos , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/genética , Animais , Células da Medula Óssea , Modelos Animais de Doenças , Vetores Genéticos , HIV , Humanos , Camundongos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução Genética , Transgenes , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/biossíntese , Proteínas do Envelope Viral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA